Walgreens said Thursday it’s getting into cell and gene therapy pharmacy services and bringing its specialty pharmacy under a new name as it navigates the future of its business.
DUBAI, UAE / MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and Singapore, today announced a EUR 16 million investment into Munich-headquartered neurocare group AG (neurocare), a leading innovator in personalized mental health care, providing solutions to empower clinicians to deliver best care to their patients. TVM Capital Healthcare's investment will enable neurocare to execute on its international growth plans, including expansion in the US and market entry into the Kingdom of Saudi Arabia, as well as support the development of new hardware and software innovations. It is the ninth investment of TVM Capital Healthcare to improve local access to quality healthcare in the MENA region.
Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9%...
Pharma companies are scaling back the use of terms like “ESG” and “diversity, equity and inclusion,” much like companies in other industries.
Tower Cold Chain, a provider of passive temperature-controlled containers, introduced the KTEvolution 12, offering a new standard in small parcel solutions for pharmaceutical products, with a unique plate design.
Australia’s Therapeutic Goods Administration (TGA) is holding a consultation into whether to change the requirements for providing instructions for use (IFU) for medical devices.
SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept, placebo-controlled, parallel group trial with a six-week treatment period and four weeks of follow up.
Genetic Technologies Announces Closing of $2 Million Registered Direct Offering
Australia's newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility.
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address...